NSE: AUROPHARMA · 23 October 2026
- Aurobindo Pharma Ltd shares declined 2.43% on 23-Oct-2026, closing at ₹1571.70 after moving between an intraday high of ₹1608.80 and a low of ₹1547.80.
- Aurobindo Pharma announced that its wholly owned subsidiary, APL Healthcare, received final approval from the US Food & Drug Administration to manufacture and market Perampanel Tablets across multiple strengths ranging from 2 mg to 12 mg. The approved product is therapeutically equivalent to Catalyst Pharmaceuticals' Fycompa tablets and addresses an estimated US market size of $67 million for the twelve months ending August 2026. Commercial rollout is slated for the third quarter of fiscal year 2027.
- Trading volume was 0.74 times the 20-day average daily volume.
Why is Aurobindo Pharma share price falling on 23 October 2026?
Aurobindo Pharma Ltd shares declined 2.43% on 23-Oct-2026, closing at ₹1571.70 after moving between an intraday high of ₹1608.80 and a low of ₹1547.80.
The stock underperformed broader market indices as the benchmark Nifty fell 0.39% and the Nifty Pharma sector index dropped 1.04%, reflecting broader weakness across pharmaceutical peers. This downward movement extends a short-term correction for the counter, which has registered a 5-day return of -6.33% and a 20-day return of -8.70%.
While recent operational updates highlight ongoing expansion—including the completion of the A1 Biochem Labs LLC acquisition in the United States on 02-Oct-2026 and the USFDA final approval for Perampanel Tablets on 03-Oct-2026—these corporate milestones serve as background context rather than direct catalysts for today's price action, which appears aligned with prevailing sector consolidation.
6.51 lakh shares traded by 23 October 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 8.82 lakh shares (0.74 times). The five-day average daily volume was 9.26 lakh shares. Separately, the NSE report for 23 October 2026 showed 3.34 lakh shares delivered, representing 51.29% of that day’s traded volume. The same report recorded 40,505 trades.
Today's 2.43% decline occurred alongside broader weakness in the Nifty Pharma sector (-1.04%) and follows a recent downward retracement in the stock over the past 5 and 20 trading sessions. In the absence of any direct same-day corporate trigger, the move reflects prevailing sector sentiment and profit-taking rather than company-specific operational developments.
Latest Company Developments
Aurobindo Pharma announced that its wholly owned subsidiary, APL Healthcare, received final approval from the US Food & Drug Administration to manufacture and market Perampanel Tablets across multiple strengths ranging from 2 mg to 12 mg. The approved product is therapeutically equivalent to Catalyst Pharmaceuticals' Fycompa tablets and addresses an estimated US market size of $67 million for the twelve months ending August 2026. Commercial rollout is slated for the third quarter of fiscal year 2027.
This approval expands the company's central nervous system product pipeline and supports future revenue generation in the regulated US generic market.
The company announced the successful completion of the acquisition of A1 Biochem Group's contract research services business through its subsidiary Apitoria Pharma. Following customary closing conditions, Apitoria holds an 80% stake in A1 Labs India, while A1 Labs USA has acquired 100% membership interest in A1 Labs LLC in North Carolina for a cash consideration of $15.247 million.
The transaction establishes a dedicated contract research, development, and manufacturing platform, enhancing the company's integration across the active pharmaceutical ingredient life cycle.
Acrotech Biopharma, a step-down subsidiary of Aurobindo Pharma, announced the U.S. launch of ADQUEY (difamilast 1%) ointment as a non-steroidal topical treatment for mild-to-moderate atopic dermatitis in patients aged 2 years and older. Concurrently, Acrotech has established a dedicated dermatology business unit to support healthcare professionals and expand commercial presence in this therapeutic area, which has an estimated U.S. market size of $1.3 billion according to IQVIA MAT.
The launch marks Acrotech's entry into the U.S. dermatology market, diversifying its portfolio into specialized proprietary medicines.
Aurobindo Pharma Limited has submitted the Exchange a copy Srutinizers report of AGM held on August 27, 2026. and voting results.
a press release dated October 03, 2026, titled "Aurobindo Pharma receives USFDA Final Approval for Perampanel Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 16.31% on 30 September 2026. This compares with 16.71% on 30 June 2026, a change of -0.40 percentage points.
The filing reported 44 MF/UTI holders.
Research & Brokerage Views
Maintained a positive view on the stock following steady operational progress and upward target revisions amid year-to-date performance.
What to Watch Next
- Execution of commercial launches including Perampanel Tablets in the third quarter of fiscal year 2027
- Integration milestones and revenue contributions from the newly acquired A1 Biochem Labs operations
- Commercial uptake of ADQUEY ointment through the newly established Acrotech dermatology business unit
- Price action relative to technical support levels amid ongoing sector-wide underperformance
Other Dated Coverage
- Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Rising 1.41% | 22 October 2026 — 22 October 2026
- Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Falling 3.08% | 19 October 2026 — 19 October 2026
- Why Aurobindo Pharma Shares Slipped 0.11% Today Amid Sector Weakness | 5 October 2026 — 5 October 2026
More Aurobindo Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Aurobindo Pharma company news?
Aurobindo Pharma announced that its wholly owned subsidiary, APL Healthcare, received final approval from the US Food & Drug Administration to manufacture and market Perampanel Tablets across multiple strengths ranging from 2 mg to 12 mg. The approved product is therapeutically equivalent to Catalyst Pharmaceuticals' Fycompa tablets and addresses an estimated US market size of $67 million for the twelve months ending August 2026. Commercial rollout is slated for the third quarter of fiscal year 2027.
How strong was Aurobindo Pharma’s trading volume?
6.51 lakh shares traded, 0.74 times the 20-day average daily volume. The price and volume data are dated 23 October 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.